Discrimination by PPADS between endothelial P2Y- And P2U-purinoceptors in the rat isolated mesenteric arterial bed

Abstract

1 The main aim of this study was to characterize the antagonistic effects of pyridoxalphosphate-6-azophenyl-2′,4′-disulphonic acid (PPADS) at coexisting endothelial P2Y- and P2U-purinoceptors. Studies were conducted in Krebs-perfused mesenteric arterial preparations isolated from the rat, with tone raised by methoxamine (5 50 μM). 2 Purine and pyrimidine compounds elicited vasodilatation with a rank order of potency of 2-methylthio ATP (2-MeSATP) = ADP > ATP = UTP > P1, P3-diadenosine triphosphate (Ap3A) > P1, P2-diadenosine pyrophosphate (Ap2A) > NADP > adenosine. 8-para-Sulphophenyltheophylline (8-PSPT; 3 μM) had no effect on vasodilator responses to 2MeSATP, ADP, ATP, UTP, Ap3A or NADP, but blocked responses to adenosine and the maximal response to Ap2A. 3 PPADS (3- 100 μM) attenuated vasodilator responses to the P2Y-selective agonists 2MeSATP and ADP, shifting the dose-response curves to the right. The pA2 values for PPADS at 2MeSATP and ADP were 5.97 ± 0.69 and 5.98 ± 0.86 respectively. In contrast, PPADS had no effect on vasodilator responses mediated by the P2U-selective agonist, UTP, or on vasodilator responses mediated by ATP. 4 PPADS (10 μM) was used to characterize responses mediated by the adenine dinucleotides; dose-response curves for vasodilator responses to Ap3A and NADP, but not those to Ap2A, were shifted to the right by PPADS. The estimated pA2 values for the effect of PPADS on Ap3A and NADP were 6.38 and 6.26 respectively. 5 Indomethacin (10 μM) had no effect on vasodilator responses to 2MeSATP, ADP, ATP or UTP. 6 In conclusion, these results show that PPADS is an antagonist at endothelial P2Y- but not P2U-purinoceptors in rat mesenteric arteries. These receptors cannot be discriminated by inhibition of prostaglandin synthesis; P2Y-purinoceptors are, however, sensitive to ADP. Selective antagonism by use of PPADS showed that ATP acts at P2U- and not P2Y-purinoccptors. Ap3A and NADP mediate vasodilatation via P2Y-purinoceptors, whereas vasodilatation to Ap2A is mediated partly via P1- and possibly via P2U-purinoceptors.